Brain metastases in patients with ALK+ non-small cell lung cancer: clinical symptoms, treatment patterns and economic burden

References

• American Cancer Society. Lung Cancer (Non-Small Cell). Atlanta, GA: American Cancer Society; 2014, 77. http://www.cancer.org/acs/groups/content/@research/documents/document/acspc-041770.pdf. Accessed August 9, 2013
   Google Scholar
• Howlader N, Noone A, Krapcho M, et al., eds. SEER Cancer Statistics Review 1975-2010. Bethesda, MD: National Cancer Institute; 2010. http://seer.cancer.gov/csr/1975_2010/. Accessed June 6, 2013
   Google Scholar
• Larsen JE, Cascone T, Gerber DE, et al. Targeted therapies for lung cancer: clinical experience and novel agents. Cancer J 2011;17:512-27
   PubMed Web of Science ®Google Scholar
• Custodio A, Méndez M, Provencio M. Targeted therapies for advanced non-small-cell lung cancer: current status and future implications. Cancer Treat Rev 2012;38:36-53
   PubMed Web of Science ®Google Scholar
• Bang Y-J. Treatment of ALK-positive non-small cell lung cancer. Arch Pathol Lab Med 2012;136:1201-4
   PubMed Web of Science ®Google Scholar
• Li Y, Ye X, Liu J, et al. Evaluation of EML4-ALK fusion proteins in non-small cell lung cancer using small molecule inhibitors. Neoplasia 2011;13:1-11
   PubMed Web of Science ®Google Scholar
• Shaw AT, Solomon B. Targeting anaplastic lymphoma kinase in lung cancer. Clin Cancer Res 2011;17:2081-6
   PubMed Web of Science ®Google Scholar
• Kim T-J, Park CK, Yeo CD, et al. Simultaneous diagnostic platform of genotyping EGFR, KRAS, and ALK in 510 Korean patients with non-small-cell lung cancer highlights significantly higher ALK rearrangement rate in advanced stage. J Surg Oncol 2014;110(3):245-51. published online May 29, 2014, doi: 10.1002/jso.23646
   Google Scholar
• Park J, Yamaura H, Yatabe Y, et al. Anaplastic lymphoma kinase gene rearrangements in patients with advanced-stage non-small-cell lung cancer: CT characteristics and response to chemotherapy. Cancer Med 2013;3:118-23
   Google Scholar
• Chun SG, Choe KS, Iyengar P, et al. Isolated central nervous system progression on Crizotinib: an Achilles heel of non-small cell lung cancer with EML4-ALK translocation? Cancer Biol Ther 2012;13:1376-83
   PubMed Web of Science ®Google Scholar
• Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007;448:561-6
   PubMed Web of Science ®Google Scholar
• Koivunen JP, Mermel C, Zejnullahu K, et al. EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin Cancer Res 2008;14:4275-83
   PubMed Web of Science ®Google Scholar
• Boland JM, Erdogan S, Vasmatzis G, et al. Anaplastic lymphoma kinase immunoreactivity correlates with ALK gene rearrangement and transcriptional up-regulation in non-small cell lung carcinomas. Hum Pathol 2009;40:1152-8
   PubMed Web of Science ®Google Scholar
• Shaw AT, Yeap BY, Mino-Kenudson M, et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol 2009;27:4247-53
   PubMed Web of Science ®Google Scholar
• Wong DW-S, Leung EL-H, So KK-T, et al. The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS. Cancer 2009;115:1723-33
   PubMed Web of Science ®Google Scholar
• Inamura K, Takeuchi K, Togashi Y, et al. EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers. J Thorac Oncol 2008;3:13-17
   PubMed Web of Science ®Google Scholar
• Takeuchi K, Choi YL, Soda M, et al. Multiplex reverse transcription-PCR screening for EML4-ALK fusion transcripts. Clin Cancer Res 2008;14:6618-24
   PubMed Web of Science ®Google Scholar
• Perner S, Wagner PL, Demichelis F, et al. EML4-ALK fusion lung cancer: a rare acquired event. Neoplasia 2008;10:298-302
   PubMed Web of Science ®Google Scholar
• Rodig SJ, Mino-Kenudson M, Dacic S, et al. Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population. Clin Cancer Res 2009;15:5216-23
   PubMed Web of Science ®Google Scholar
• Doebele RC, Lu X, Sumey C, et al. Oncogene status predicts patterns of metastatic spread in treatment-naive nonsmall cell lung cancer. Cancer 2012;118:4502-11
   PubMed Web of Science ®Google Scholar
• Kang HJ, Lim H-J, Park JS, et al. Comparison of clinical characteristics between patients with ALK-positive and EGFR-positive lung adenocarcinoma. Respir Med 2014;108:388-94
   PubMed Web of Science ®Google Scholar
• Shaw AT, Kim D-W, Nakagawa K, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 2013;368:2385-94
   PubMed Web of Science ®Google Scholar
• Kim D-W, Mehra R, Tan DS-W, et al. Ceritinib in Advanced Anaplastic Lymphoma Kinase (ALK)-rearranged (ALK+) Non-small Cell Lung Cancer (NSCLC) – Results of the ASCEND-1 Trial (#8003). J Clin Oncol 2014;32:5s:abstr 8003
   Google Scholar
• Wen PY, Loeffler JS. Overview of the clinical manifestations, diagnosis, and management of patients with brain metastases. Wolter Kluwer Health; 2013, p 1–15. UpToDate, Inc., 95 Sawyer Rd., Waltham, MA 02453
   Google Scholar
• Gofton TE, Graber J, Carver A. Identifying the palliative care needs of patients living with cerebral tumors and metastases: a retrospective analysis. J Neurooncol 2012;108:527-34
   PubMed Web of Science ®Google Scholar
• Bauml J, Mick R, Zhang Y, et al. Determinants of survival in advanced non–small-cell lung cancer in the era of targeted therapies. Clin Lung Cancer 2013;14:581-91
   PubMed Web of Science ®Google Scholar
• Ray S, Dacosta-Byfield S, Ganguli A, et al. Comparative analysis of survival, treatment, cost and resource use among patients newly diagnosed with brain metastasis by initial primary cancer. J Neurooncol 2013;114:117-25
   PubMed Web of Science ®Google Scholar
• Patchell RA. The management of brain metastases. Cancer Treat Rev 2003;29:533-40
   PubMed Web of Science ®Google Scholar
• Taimur S, Edelman MJ. Treatment options for brain metastases in patients with non-small-cell lung cancer. Curr Oncol Rep 2003;5:342-6
   PubMedGoogle Scholar
• Lu-Emerson C, Eichler AF. Brain metastases. Continuum (Minneap Minn) 2012;18:295-311
   PubMedGoogle Scholar
• Tang V, Rathbone M, Park Dorsay J, et al. Rehabilitation in primary and metastatic brain tumours: impact of functional outcomes on survival. J Neurol 2008;255:820-7
   PubMed Web of Science ®Google Scholar
• Schubart JR, Kinzie MB, Farace E. Caring for the brain tumor patient: family caregiver burden and unmet needs. Neuro Oncol 2008;10:61-72
   PubMed Web of Science ®Google Scholar
• Welzel G, Fleckenstein K, Schaefer J, et al. Memory function before and after whole brain radiotherapy in patients with and without brain metastases. Int J Radiat Oncol Biol Phys 2008;72:1311-18
   PubMed Web of Science ®Google Scholar
• Soffietti R, Rudà R, Trevisan E. Brain metastases: current management and new developments. Curr Opin Oncol 2008;20:676-84
   PubMed Web of Science ®Google Scholar
• Ricciardi S, de Marinis F. Multimodality management of non-small cell lung cancer patients with brain metastases. Curr Opin Oncol 2010;22:86-93
   PubMed Web of Science ®Google Scholar
• Narita Y, Shibui S. Strategy of surgery and radiation therapy for brain metastases. Int J Clin Oncol 2009;14:275-80
   PubMed Web of Science ®Google Scholar
• Nieder C, Norum J, Stemland JG, et al. Resource utilization in patients with brain metastases managed with best supportive care, radiotherapy and/or surgical resection: a Markov analysis. Oncology 2010;78:348-55
   PubMed Web of Science ®Google Scholar
• Takura T, Hayashi M, Muragaki Y, et al. [Study on medical economic evaluation methods for metastatic brain tumors therapy]. No Shinkei Geka 2010;38:629-37
   PubMedGoogle Scholar
• Quan H, Sundararajan V, Halfon P, et al. Coding algorithms and for defining comorbidities data in ICD-9-CM administrative. Med Care 2005;43:1130-9
   PubMed Web of Science ®Google Scholar
• Zhang N-N, Liu Y-T, Ma L, et al. The molecular detection and clinical significance of ALK rearrangement in selected advanced non-small cell lung cancer: ALK expression provides insights into ALK targeted therapy. PLoS One 2014;9:e84501
   PubMed Web of Science ®Google Scholar
• Paik JH, Choi C-M, Kim H, et al. Clinicopathologic implication of ALK rearrangement in surgically resected lung cancer: a proposal of diagnostic algorithm for ALK-rearranged adenocarcinoma. Lung Cancer 2012;76:403-9
   PubMed Web of Science ®Google Scholar
• Fallet V, Cadranel J, Doubre H, et al. Prospective screening for ALK: clinical features and outcome according to ALK status. Eur J Cancer 2014;50:1239-46
   PubMed Web of Science ®Google Scholar
• Sørensen JB, Hansen HH, Hansen M, Dombernowsky P. Brain metastases in adenocarcinoma of the lung: frequency, risk groups, and prognosis. J Clin Oncol 1988;6:1474-80
   PubMed Web of Science ®Google Scholar
• Jena A, Taneja S, Talwar V, et al. Magnetic resonance (MR) patterns of brain metastasis in lung cancer patients: correlation of imaging findings with symptom. J Thorac Oncol 2008;3:140-4
   PubMed Web of Science ®Google Scholar
• Komatsu T, Kunieda E, Oizumi Y, et al. Clinical characteristics of brain metastases from lung cancer according to histological type: pretreatment evaluation and survival following whole-brain radiotherapy. Mol Clin Oncol 2013;1:692-8
   Google Scholar
• Ferrigno D, Buccheri G. Cranial computed tomography as a part of the initial staging procedures for patients with non-small-cell lung cancer. Chest 1994;106:1025-9
   PubMed Web of Science ®Google Scholar
• Haura EB. Treatment of advanced non-small-cell lung cancer: a review of current randomized clinical trials and an examination of emerging therapies. Cancer Control 2001;8:326-36
   PubMedGoogle Scholar
• Frampton JE. Crizotinib: a review of its use in the treatment of anaplastic lymphoma kinase-positive, advanced non-small cell lung cancer. Drugs 2013;73:2031-51
   PubMed Web of Science ®Google Scholar
• Wu C, Li YL, Wang ZM, et al. Gefitinib as palliative therapy for lung adenocarcinoma metastatic to the brain. Lung Cancer 2007;57:359-64
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network. Non-small cell lung cancer, version 4. 2014. Fort Washington, PA: National Comprehensive Cancer Network, 2014. p 1-147
   Google Scholar